The shadow of generic competition has long loomed over copyright’s iconic drug, Viagra, triggering questions about the future of connected medicinal ventures. While early times saw substantial returns, the intellectual property expiration has opened the way for cheaper substitutes, potentially diminishing profitability and creating a real risk fo